These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


192 related items for PubMed ID: 18054737

  • 21. The role of the liver on post-prandial glycaemia--emphasis on hepatic glucose uptake.
    Kawamori R.
    Int J Clin Pract Suppl; 2000 Sep; (112):19-22. PubMed ID: 11064947
    [No Abstract] [Full Text] [Related]

  • 22. Sulfonylureido thiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of type-2 diabetes.
    Kitas E, Mohr P, Kuhn B, Hebeisen P, Wessel HP, Haap W, Ruf A, Benz J, Joseph C, Huber W, Sanchez RA, Paehler A, Benardeau A, Gubler M, Schott B, Tozzo E.
    Bioorg Med Chem Lett; 2010 Jan 15; 20(2):594-9. PubMed ID: 19969452
    [Abstract] [Full Text] [Related]

  • 23. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E, Minuto F, Colao A, Ferone D.
    Acta Diabetol; 2009 Jun 15; 46(2):85-95. PubMed ID: 19322513
    [Abstract] [Full Text] [Related]

  • 24. Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.
    Thomson SA, Banker P, Bickett DM, Boucheron JA, Carter HL, Clancy DC, Cooper JP, Dickerson SH, Garrido DM, Nolte RT, Peat AJ, Sheckler LR, Sparks SM, Tavares FX, Wang L, Wang TY, Weiel JE.
    Bioorg Med Chem Lett; 2009 Feb 15; 19(4):1177-82. PubMed ID: 19138846
    [Abstract] [Full Text] [Related]

  • 25. Efficacy of coumarin on hepatic key enzymes of glucose metabolism in chemical induced type 2 diabetic rats.
    Pari L, Rajarajeswari N.
    Chem Biol Interact; 2009 Oct 30; 181(3):292-6. PubMed ID: 19647726
    [Abstract] [Full Text] [Related]

  • 26. Contributions of hepatic gluconeogenesis suppression and compensative glycogenolysis on the glucose-lowering effect of CS-917, a fructose 1,6-bisphosphatase inhibitor, in non-obese type 2 diabetes Goto-Kakizaki rats.
    Yoshida T, Okuno A, Takahashi K, Ogawa J, Hagisawa Y, Kanda S, Fujiwara T.
    J Pharmacol Sci; 2011 Oct 30; 115(3):329-35. PubMed ID: 21350313
    [Abstract] [Full Text] [Related]

  • 27. Establishment of liver specific glucokinase gene knockout mice: a new animal model for screening anti-diabetic drugs.
    Zhang YL, Tan XH, Xiao MF, Li H, Mao YQ, Yang X, Tan HR.
    Acta Pharmacol Sin; 2004 Dec 30; 25(12):1659-65. PubMed ID: 15569412
    [Abstract] [Full Text] [Related]

  • 28. [Molecular targets for new drug discovery to treat type 2 diabetes and obesity].
    Bastarrachea RA, Montero JC, Saavedra-Gajardo I, Cerda-Flores R, Machado-Domínguez A, Comuzzie AG.
    Rev Med Chil; 2008 Jan 30; 136(1):107-17. PubMed ID: 18483661
    [Abstract] [Full Text] [Related]

  • 29. Beta-cell function and mass in type 2 diabetes.
    Larsen MO.
    Dan Med Bull; 2009 Aug 30; 56(3):153-64. PubMed ID: 19728971
    [Abstract] [Full Text] [Related]

  • 30. Managlinat dialanetil, a fructose-1,6-bisphosphatase inhibitor for the treatment of type 2 diabetes.
    Wang Y, Tomlinson B.
    Curr Opin Investig Drugs; 2007 Oct 30; 8(10):849-58. PubMed ID: 17907062
    [Abstract] [Full Text] [Related]

  • 31. Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics.
    Dang Q, Brown BS, Liu Y, Rydzewski RM, Robinson ED, van Poelje PD, Reddy MR, Erion MD.
    J Med Chem; 2009 May 14; 52(9):2880-98. PubMed ID: 19348494
    [Abstract] [Full Text] [Related]

  • 32. Reversible hyperglycemia in rats following acute exposure to acephate, an organophosphorus insecticide: role of gluconeogenesis.
    Joshi AK, Rajini PS.
    Toxicology; 2009 Mar 04; 257(1-2):40-5. PubMed ID: 19118596
    [Abstract] [Full Text] [Related]

  • 33. MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.
    Erion MD, van Poelje PD, Dang Q, Kasibhatla SR, Potter SC, Reddy MR, Reddy KR, Jiang T, Lipscomb WN.
    Proc Natl Acad Sci U S A; 2005 May 31; 102(22):7970-5. PubMed ID: 15911772
    [Abstract] [Full Text] [Related]

  • 34. Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes.
    Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.
    J Med Chem; 2009 Oct 08; 52(19):6142-52. PubMed ID: 19746978
    [Abstract] [Full Text] [Related]

  • 35. Phytogenic Polyphenols as Glycogen Phosphorylase Inhibitors: The Potential of Triterpenes and Flavonoids for Glycaemic Control in Type 2 Diabetes.
    Leonidas DD, Hayes JM, Kato A, Skamnaki VT, Chatzileontiadou DS, Kantsadi AL, Kyriakis E, Chetter BA, Stravodimos GA.
    Curr Med Chem; 2017 Oct 08; 24(4):384-403. PubMed ID: 27855623
    [Abstract] [Full Text] [Related]

  • 36. Protection of pancreatic beta-cells: is it feasible?
    Bonora E.
    Nutr Metab Cardiovasc Dis; 2008 Jan 08; 18(1):74-83. PubMed ID: 18096375
    [Abstract] [Full Text] [Related]

  • 37. Epigenomic derangement of hepatic glucose metabolism by feeding of high fructose diet and its prevention by Rosiglitazone in rats.
    Yadav H, Jain S, Yadav M, Sinha PR, Prasad GB, Marotta F.
    Dig Liver Dis; 2009 Jul 08; 41(7):500-8. PubMed ID: 19196556
    [Abstract] [Full Text] [Related]

  • 38. New treatments in type 2 diabetes: a focus on the incretin-based therapies.
    Barnett AH.
    Clin Endocrinol (Oxf); 2009 Mar 08; 70(3):343-53. PubMed ID: 18771570
    [Abstract] [Full Text] [Related]

  • 39. Inhibition of the interaction between protein phosphatase 1 glycogen-targeting subunit and glycogen phosphorylase increases glycogen synthesis in primary rat hepatocytes.
    Zibrova D, Grempler R, Streicher R, Kauschke SG.
    Biochem J; 2008 Jun 01; 412(2):359-66. PubMed ID: 18298402
    [Abstract] [Full Text] [Related]

  • 40. Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs.
    Efendic S, Alvarsson M, Brismar K, Wagner H.
    Acta Physiol (Oxf); 2008 Jan 01; 192(1):117-25. PubMed ID: 18171434
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 10.